By Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Of the recurring themes that tend to circulate in the drug development discourse,  China is a uniquely fascinating and polarizing subject.

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC As biotech companies tackle the escalating time and cost of clinical trials, the decision to conduct early-stage, proof-of-concept studies outside the U.S. is

By Cody Tranbarger, Entrepreneur In Residence at Atlas Venture, as part of the From The Trenches feature of LifeSciVC   What if the biggest obstacle to the next generation of I&I therapeutics isn’t finding better targets — but accepting that

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC In early 2009, when global markets were bottoming out, you can imagine what it felt like walking the halls of the JPM Healthcare

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. I’m not a resolutions person but I’ve always loved the start of the year – there is something about turning the page on

By Jason Campagna, biotech executive, as part of the From The Trenches feature of LifeSciVC I recently joined Inventiva Pharma, a late-stage company developing a therapeutic for metabolic disease and MASH, a field that is both scientifically complex and once

By, Arthur Tzianabos, CEO of Lifordi, as part of the From The Trenches feature of LifeSciVC I often hear biotech leaders refer to their company’s technology and approach in terms of the “secret sauce” or “how the sausage gets made.”

This year has truly been a rollercoaster!  The markets started off with optimism, but then collapsed into the spring, only to rebound with enthusiasm in recent months. The cadence of M&A has picked up, creating a tailwind for the sector. 

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Hospitals were never meant to be familiar to me, yet for over twenty years MD Anderson became a place I could navigate by heart: the

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC I’m far from the first person to point out the prolonged market challenges that have depressed the biotech fundraising environment over the past

By Mike Gilman, serial entrepreneur and veteran biotech executive, as part of the From The Trenches feature of LifeSciVC My thesis advisor, Mike Chamberlin, passed away last week. I owe much of who I am as a scientist to him.

At the end of the day, biotech venture capital is a business and driving returns is the ultimate metric. For twenty years, to deliver on that, I’ve embraced what I call the “first principle” of early stage biotech investing: if